We are witnessing a decentralization and dissemination of innovation and entrepreneurial hubs, shifting attention toward alternative and unexpected jurisdictions with previously unexplored opportunities (e.g.,Estonia,Singapore). Moreover, given that teh life sciences and health entrepreneurship sector is composed of multiple segments with distinct characteristics, additional forces are accelerating this transformation: the democratization of access to tools such as AI, the emergence of alternative research hubs (e.g., China, South Korea, India), the rise of markets with regulatory and strategic advantages, and the digitalization and global circulation of medical data (e.g., global biobank networks, AI-based diagnostic development using multinational datasets). Together, these developments are collectively reshaping the global landscape.

Simultaneously occurring, many may assume that the Greek life sciences and health innovation ecosystem is underdeveloped and burdened by long-standing challenges.this is not unique to Greece; several talent-rich countries in Eastern and Southern europe exhibit a similar pattern. However, evaluating Greece solely through the lens of a single prosperous ecosystem – such as Cambridge (UK) or Cambridge (US) – with their well-known advantages (the presence of prestigious academic and research institutions in close proximity, geographic concentration that fosters inspiration, density, and serendipitous synergies, standardized intellectual property pathways, and abundant access to risk-tolerant capital) is misleading. It is a trap. What may appear as underdevelopment could instead represent slow but steady maturation – an incremental fermentation that is now enabling the ecosystem to form a more dynamic and distinctive character.With a proven track record and success stories in the broader field of innovation, Greece is now positioned to focus on more specialized domains such as health and life sciences. This shift is already visible in recent public-private initiatives aimed at improving access to infrastructure,networks and mentorship,as well as programs encouraging scientists to adopt an entrepreneurial mindset and return from abroad. These efforts are beginning to reinforce the local life sciences and health innovation landscape. Notably, the growing presence of health-focused venture capital firms establishing operations in Greece and actively seeking investment opportunities across the region reflects this momentum and invites deeper analysis.

Could greece become one of these emerging life-sciences and health innovation hubs? Recent signs – a modest brain-gain, growing investment interest, and a number of individual initiatives – suggest it can. How are ecosystem-dependent mechanisms currently functioning in the Greek context and what adjustments and improvements are needed moving forward? Coupled with long-standing local strengths and ecosystem-adjusted endeavors, these developments could drive home-grown innovation and translation of it into a real-world, global impact. There is both much for Greece to learn and much it can teach. To explore these questions, five Greeks who occupy key local roles and who also have professional exposure abroad – people who have chosen to found organizations, repatriate their practices, or bring programs home – share their views and insights.

Defining greece’s unique landscape: A paradox of strength without translation

There is unanimous agreement that Greece is an under-saturated surroundings with an abundance of human resources eager to create value, and the necessary means to do so are gradually becoming established within the country’s reality. “Greece consistently produces a high number of top-tier scientists – particularly when including the Greek diaspora – both highly skilled and remarkably loyal. The next country with a higher number of scientists than Greece compared to GDP is the United Kingdom, which has more than double the GDP per capita,” notes Ioanna Mylonaki, partner at Untethered Ventures.Victoria Kimonides, CEO of Biomet.life and member of the board of directors of BioInnovation Greece, reinforces this, adding: “On the research front, although Greek scientists do not always lead EU-funded projects, their participation in research consortia is quite high, as are the associated high-impact publications. Bio-innovation activity and opportunities span the entire spectrum – from biotechnology and bioinformatics that can support the evolution of customary pharma, to the broader bioeconomy.”

She continues: “The diaspora is a driving force, as a significant number of Greek scientists and bio-entrepreneurs abroad are re-engaging with the domestic ecosystem, bringing back expertise, networks, know-how and, in certain specific cases, capital.” Indeed, the Greek diaspora appears to be pivotal in the positive transformation taking place. Stefanos Capsaskis,partner at Corallia Ventures,explores this further,highlighting the distinctive advanta### Greece’s Biotech potential: Navigating Challenges and Charting a realistic Path

Greece’s burgeoning biotech sector faces a complex landscape of challenges and opportunities. While the country boasts a strong scientific base and increasing investor interest, systemic hurdles impede its full potential.A key issue is the risk aversion prevalent in the investment climate. As Dr. Vassiliki Theodoropoulou of the Hellenic BioCluster notes, “It’s arduous to bootstrap and seek grant funding. The fact that there is limited appetite to take risks does not help.” Notably, a significant share of the increasing influx of investment capital is not flowing to early-stage biotech companies; the number of large later-stage rounds (Series C and D) is rising as well.major efforts are being made to bridge this funding gap: “The European Investment Fund has taken a decisive step to strengthen the ecosystem. Through the EquiFund II mandate, new healthcare- and life-science-focused venture funds will bring the specialized knowledge and capital needed to nurture high-potential companies, further supported by the Hellenic Development Bank of Investments. This coordinated effort is already translating into tangible progress: At least four dedicated healthcare and life science funds are now under formation in Greece, aiming to inject more than €150 million into the market,” Mylonaki says.

This lack of coordination, predictability, and enabling mechanisms inevitably negatively impacts the general entrepreneurial culture. As Kimonides notes: “Looking at the profile of the founders, the biggest challenge is the lack of business mindset.” this gap – common in research-driven but commercially immature ecosystems – creates a bottleneck between invention and venture creation. In addition, significant legal constraints remain, such as regarding clinicians’ ability to engage in entrepreneurial activities, with recent legislation only superficially framed as supportive.Under the current legal framework, Greek medics cannot pursue entrepreneurial activities while practicing, preventing them from transforming real-world problems into ventures – an issue that demands urgent reform if Greece aims for translational medicine and medtech to thrive.

Sapounas describes another problematic aspect of the situation: “access to medicines is another key issue. High clawbacks and tight hospital budgets can discourage new launches and strain the system. We need a more stable, multi-year approach that ties clawbacks to real-world outcomes and value, while simultaneously occurring boosting uptake of generics and biosimilars fairly, without punishing true innovation. Measures like the cap on patient co-pays for generics are a positive step toward equity but we need a broader, coherent framework.” Innovation friendliness doesn’t necessarily reflect healthcare systems with high willingness-to-pay thresholds, as there are alternative ways to embrace innovation without substantial allocation of state capital. Greece’s private healthcare providers, generally more agile and quicker to spend, could be used as an initial barrier to test the Greek population-adjusted effectiveness and cost-efficiency of novel diagnostics and therapeutics. “Greece stands to benefit greatly by adopting breakthrough innovations that reduce costs and enhance care,then scaling these solutions globally,” Mylonaki underscores.

Future perspectives: A realistic, high-potential route for Greece

Looking ahead, what structural reforms should Greece implement and promote to convert emerging opportunities into concrete outcomes? Greece must chart its own pathway, leveraging its unique strengths rather than attempting to replicate models that emerged under entirely different conditions. Identifying the country’s natural niche is thus essential. Existing infrastructure gaps already shape the direction of innovation, orienting activity toward specific segments. As Kimonides notes, “wet labs, GMP facilities, and clinical trial networks” remain limited, pushing many early ventures toward digital products rather than biotech R&D that requires substantial physical infrastructure. Mylonaki echoes this trajectory: “Our fund focuses on healthtech – spanning digital health, AI- and data-driven R&D enablement, healthcare infrastructure, and medtech.” Yet infrastructure constraints do not preclude other strategic avenues. Sapounas highlights an often underappreciated chance: “We should not forget manufacturing. Without skilled people in GMP and operations, we will hit a ceiling. Targeted postgraduate programs and industry residencies can close that gap. And with targeted support for biologics, sterile manufacturing, and advanced therapies, Greece can scale production, boost exports, and keep more of the innovation pipeline inside the country rather than watching ideas fly abroad.” Tzoukas further emphasizes “the expansion of pharmaceutical and biotech services that can cater to global clients, leveraging Greece’s skilled workforce, cost advantages, and strategic geographic position” as one of the country’s most promising routes. Indeed, greece has the talent base to support CROs, CDMOs, AI-enabled drug discovery services, and specialized research platforms serving international clients – domains where expertise, not large volumes of long-term capital, defines competitiveness.

A strategic principle for Greece’s n

Greece Seeks to Transform into a Leading Biotech Hub

Greece is making a concerted effort to establish itself as a significant player in the biotechnology and life sciences sector. the country recognizes its scientific strengths and aims to translate them into economic growth and improved patient care. But it won’t be easy.

A key focus is aligning with European regulations and processes. “Our timelines and processes in greece must align tightly with the Joint Clinical Assessments at EU level to avoid delays for patients here,” explains a leading industry voice. Offering parallel scientific advice and integrating EU assessments into national decisions are crucial steps. It’s a pivotal moment for Europe, with changes happening in clinical trial regulation (CTR), the European health Data Space (EHDS), and Health Technology Assessment (HTA) reform. Greece can choose to lead or react.

Better coordination, transparent performance reporting, streamlined approvals, and investment in data and skills are all essential. Building strong partnerships between research institutions, hospitals, industry, and the government is also vital.The goal? To turn scientific advancements into jobs and, most importantly, better healthcare for Greek citizens.

Innovation within the healthcare system itself is also a priority. Embedding programs that combine medical expertise with entrepreneurship – similar to the NHS Clinical Entrepreneur model – could substantially benefit the public healthcare system.

However, funding and talent remain significant challenges. While capital and infrastructure are critically important, attracting and retaining skilled professionals is critical. Brain drain continues,despite efforts to incentivize returns. Kimonides emphasizes that attracting top talent requires offering positions with genuine growth potential, focusing on skilling and learning opportunities, not just job offers.

She advocates for cross-disciplinary bio-entrepreneurship training that connects science, business, and policy. This training should be co-designed with the industry and learn from markets that have already navigated similar journeys. Access to funding is also key. Biotech and life-sciences specialized funds,supported by the European Investment Fund (EIF) and the Hellenic Development bank (HDBI) Technology Transfer funds,will help address this challenge. Programs like Elevate Greece and bilateral collaborations between countries can also facilitate cross-border partnerships.